Navigation Links
Combined inhibition of VEGF and c-MET can decrease metastasis
Date:2/24/2012

  • Inhibition of VEGF increased c-MET expression in tumors.
  • Invasion and metastasis were blocked by inhibition of VEGF plus c-MET.
  • Dual VEGF/c-MET inhibitors are in late-stage clinical trials.

PHILADELPHIA Dual inhibition of vascular endothelial growth factor and c-MET signaling inhibited tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer, according to a paper published in Cancer Discovery, the newest journal of the American Association for Cancer Research.

"Inhibition of VEGF signaling plus c-MET signaling results in a synergistic effect on tumors that leads to slowing of tumor growth and decreased invasiveness and metastasis," said lead researcher Donald M. McDonald, M.D., Ph.D., a professor at the University of California San Francisco Comprehensive Cancer Center.

Previous laboratory research had shown that inhibition of VEGF signaling with agents like bevacizumab or sunitinib can give rise to a number of side effects including increased tumor invasion and metastasis.

What was not known was whether anti-VEGF therapy results in elevated c-MET expression, which has been previously shown to promote tumor cell invasiveness and metastasis. To determine this, McDonald and colleagues conducted a two-phase laboratory study. They treated mice engineered to develop pancreatic neuroendocrine tumors with an anti-VEGF antibody, which reduced tumor size but increased invasiveness and metastasis. This treatment also increased tumor hypoxia and expression and activity of c-MET.

However, when both VEGF and c-MET signaling were inhibited simultaneously, there was a reduction in invasion and metastasis. The researchers tested three c-MET inhibitors: crizotinib and PF-04217903, which target c-MET but not VEGF signaling, and cabozantinib, a dual inhibitor that blocks VEGF and c-MET signaling.

McDonald said they conducted their initial study in neuroendocrine pancreatic tumors because the genetic mouse model of these tumors has been studied so extensively, and then observed the effect in other tumors as well.

"The intent of this study was to explore a mechanism, and there is no indication that this effect will be confined to pancreatic tumors," he said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combined oral contraceptive pill helps painful periods
2. PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies
3. Combined arterial imaging technology reveals both structural and metabolic details
4. Novel combined therapy extends life, diminishes pain in brain cancer patients
5. Ultrasound combined with pre-operative MRI is cost effective in evaluating rotator cuff tears
6. Combined imaging technologies may better identify cancerous breast lesions
7. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
8. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
9. New Laser Technology Combined with Manual Physical Therapy Offer Pain Relief to Chronic Pain Sufferers
10. Singapore Performs Asia's First Combined Heart and Liver Transplant
11. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Miami, FL (PRWEB) , ... April 26, 2017 , ... ... twenty-fifth anniversary as a dentist. , “I could have never imagined back in 1991 ... and personally,” said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has ...
(Date:4/26/2017)... Iowa (PRWEB) , ... April 26, 2017 , ... ... DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how ... and help farmers produce more and better food, with fewer resources. It highlights ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
Breaking Medicine Technology: